Home HIV shots by loved ones could revolutionize care
NCT ID NCT06488846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a trained friend, family member, or partner can safely give long-acting HIV injections at home. It involves 1,000 people with HIV who are already on the injectable treatment and have the virus under control. The goal is to make it easier for people to stick with their HIV medication and close gaps in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
PWH who have been prescribed injectable cabotegravir/rilpivirine (CAB/RPV) as part of their routine care who have clinician approval to participate in the home-based program.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: PWH: * Age ≥18 years, patient receiving care at partnering clinical sites; * can identify a support person injector (i.e., family, friend, or partner) who is willing and able to provide injections; * has received at least the loading dose of cabotegravir/rilpivirine CAB/RPV (i.e., 600mg/900mg IM) without serious adverse events; * is virologically suppressed (HIV RNA \<50 copies/mL); * has no history of treatment failure; * has no known or suspected resistance to either RPV or CAB; * is interested in receiving home-based injections; is approved by their clinical team as a candidate for home-based injections; * has the intention to use CAB/RPV for at least 12 months; * and is willing and able to give informed consent. Treatment Buddy: * Age ≥18 years, * identified by the PWH, * is willing and able to provide monthly or bimonthly LAI-ART injections at the PWH's place of residence, and * is willing and able to give informed consent. Exclusion Criteria: PWH: * \<18 years of age, not receiving care at partnering clinic sites, * cannot identify a support person injector, * has not received at least the loading dose of CAB/RPV, * had serious adverse events with CAB/RPV with the loading dose, * is not virologically suppressed, * has a history of treatment failure, * has a known or suspected resistance to either RPV or CAB, * is not interested in receiving home-based injections, * is not approved but their clinical team as a candidate for home-based injections; * does not have the intention to use CAB/RPV for at least 12 months; * and is not willing or unable to give informed consent. Treatment Buddy: * \<18 years of age, * is not willing or unable to provide monthly or bimonthly LAI-ART injections at the PWH's place of residence, and * is not willing or unable to give informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Division of Prevention Science, Center for AIDS Prevention Studies (CAPS)
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Session couples program cut drug use and HIV risk?
- Decades of HIV data could reveal which treatments last
- Can testing together again keep male couples HIV-Free?
- Can a rapid HIV test get people treated sooner?
- Can Same-Day HIV prevention reach people before infection takes hold?
- New injectable HIV prevention drug tested in healthy volunteers